Aktie NEW YORK GLOBAL INNOVATIONS INC
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen New York Global Innovations Inc Other OTC

Aktien

US45727E1064

Schlusskurs Other OTC
Andere Börsenplätze
- USD - Intraday Chart für New York Global Innovations Inc
2023 Manuka, Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023 CI
2023 Manuka, Inc. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 30. Juni 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Manuka, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Manuka Announces Review of Strategic Alternatives
Manuka, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Manuka, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
ARTEMIS THERAPEUTICS, INC. - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
ARTEMIS THERAPEUTICS, INC. - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
ARTEMIS THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)
Artemis Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Artemis Therapeutics Inc. Auditor Raises 'Going Concern' Doubt
ARTEMIS THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Artemis Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
ARTEMIS THERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
ARTEMIS THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Artemis Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
ARTEMIS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
ARTEMIS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
Artemis Therapeutics Inc. Announces Executive Changes
Artemis Therapeutics : Opinion on the Financial Statements - Form 8-K
ARTEMIS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Results of Operations and Financial Condition, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Change in Shell Company Status, Financial Statements and Exhibits (form 8-K)
Manuka Ltd completed the acquisition of Artemis Therapeutics Inc. in a reverse merger transaction.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2DHV6 Aktie
  4. Aktie
  5. Nachrichten New York Global Innovations Inc
  6. Andere Sprachen